#DNA-encoded compound library

[cdmoservices]

Aurigene Pharmaceutical Services, in strategic collaboration with Vipergen, offers advanced DNA Encoded Library (DEL) screening services designed to expedite hit identification and enhance drug discovery success rates. This integrated platform enables the screening of over a billion small-molecule compounds, either in living cells or with purified target proteins, providing a comprehensive approach to target engagement.

[govindtbrc]

Comprehensive Analysis and Forecast of the DNA Encoded Semiconductor Libraries Market up to 2033

Market Definition

The DNA encoded semiconductor libraries market involves the development and use of semiconductor libraries that are encoded with DNA sequences for applications in fields like drug discovery, biotechnology, and materials science. These semiconductor libraries integrate DNA-based encoding techniques with semiconductor technology, enabling the creation of vast libraries of molecules or compounds that can be screened for specific properties or interactions. The use of DNA as an encoding medium allows for the rapid generation and analysis of diverse molecular structures, which is crucial for innovations in personalized medicine, targeted therapies, and advanced material design.

To Know More @ https://www.globalinsightservices.com/reports/DNA-Encoded-Semiconductor-Libraries-Market

DNA Encoded Semiconductor Libraries Market is anticipated to expand from 4.2 billion in 2024 to 9.8 billion by 2034, growing at a CAGR of approximately 8.8%.

Market Outlook

The DNA encoded semiconductor libraries market is poised for significant growth, driven by advancements in biotechnology, semiconductor technology, and the increasing need for faster, more efficient drug discovery and material development processes. DNA encoded libraries offer a unique combination of high-throughput screening, versatility, and precision, making them invaluable tools for researchers looking to identify novel bioactive compounds, potential drug candidates, and new materials.

In the pharmaceutical and biotechnology industries, DNA encoded libraries are revolutionizing drug discovery by enabling the rapid identification of lead compounds that can be further developed into therapeutic agents. By encoding large numbers of chemical compounds on DNA strands, researchers can quickly screen vast libraries of molecules for specific biological activities, dramatically accelerating the process of drug development.

The market is also benefiting from the increasing interest in personalized medicine, as DNA encoded libraries facilitate the development of drugs that are tailored to an individual’s genetic makeup, improving the efficacy and safety of treatments. Additionally, the ability to design and synthesize new materials with specific electronic, optical, or mechanical properties through DNA encoded libraries opens up new possibilities in semiconductor and nanotechnology fields, further driving market growth.

Request the sample copy of report @ https://www.globalinsightservices.com/request-sample/GIS10578

[willyskristina]

Compound Management

Compound Management Market Size, Share, Trends: Brooks Automation Leads

Integration of Artificial Intelligence and Machine Learning in Compound Management Systems Revolutionizes Sample Tracking and Analysis

Market Overview:

The global compound management market is projected to grow at a CAGR of 14.2% from 2024 to 2031, reaching USD 724.3 million by 2031. North America dominates the market due to increasing drug discovery activities, rising demand for outsourcing compound management services, and the growing adoption of automated compound management systems. The market is expanding rapidly, driven by the increasing complexity of drug development procedures, the growing number of drug candidates in pharmaceutical pipelines, and the need for efficient storage and retrieval of chemical and biological samples. There is a significant transition to automated methods and integrated software solutions to enhance productivity and reduce human error in compound library management.

DOWNLOAD FREE SAMPLE

Market Trends:

The compound management industry is witnessing a significant shift towards intelligent systems, driven by the integration of artificial intelligence (AI) and machine learning (ML) technologies. These technologies are revolutionizing sample tracking and analysis, with companies investing in smart compound management platforms that can predict sample degradation, optimize storage conditions, and streamline retrieval processes. For example, Brooks Life Sciences' BioStore III Cryo automated storage system uses AI algorithms to predict and prevent sample integrity issues. This trend is further supported by the rising demand for predictive analytics in drug discovery.

Market Segmentation:

Chemical compounds dominate the compound management market, accounting for a significant share due to the widespread use of small molecule libraries in drug discovery and development. The segment has seen substantial progress thanks to innovations in storage technologies, sample tracking systems, and integration with high-throughput screening platforms. Efficient management of chemical compound libraries is crucial for expediting drug discovery. Advanced compound management systems allow researchers to store, retrieve, and track millions of compounds efficiently, reducing the time and cost of early-stage drug development. The growth of DNA-encoded libraries (DELs) has further increased the demand for advanced chemical compound management solutions.

Market Key Players:

Brooks Automation (Azenta Life Sciences)

Hamilton Company

TTP Labtech (SPT Labtech)

Tecan Group

Evotec

Titian Software

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[colinwilson11]

Global DNA Encoded Libraries - A Revolutionary Approach To Drug Discovery

DNA encoded libraries are a powerful new method for drug discovery. They allow scientists to rapidly screen billions of drug-like small molecules to find new candidates for drug development.

How do they work? 

DELs work by attaching short Global DNA Encoded Libraries tags to individual drug-like small molecules. Each small molecule is given a unique DNA barcode. Large libraries containing billions of these DNA-tagged molecules can then be synthesized and stored.

To screen the library, the tagged molecules are incubated with a biological target, like a protein involved in disease. Any molecules that bind to the target will be captured along with their unique DNA barcode. Scientists can then determine what molecules bound by decoding the DNA sequences. This allows high-throughput identification of potential lead compounds for drug development from enormous libraries of molecules.

Advantages Over Traditional Screening Methods 

Traditional high-throughput screening methods for drug discovery analyze molecules one at a time in microplate wells. They can only test around one million compounds per day. DNA encoded libraries overcome this limitation by allowing all the molecules in a library to be screened simultaneously. Experiments can identify binders from billions of molecules in a single assay.

They also have advantages over fragment-based drug discovery methods. Fragment screens identify small chemical fragments that bind to targets, which must then be elaborated into lead compounds. They start with drug-sized molecules, so hits require less optimization.

Global Expansion Of Dels Technology

Since their development in 2015, they have revolutionized drug discovery across the pharmaceutical and academic research. Major pharmaceutical companies like Pfizer, GSK, Janssen, and Sanofi have all established it screening programs.

In 2020, Anthropic established the world's largest public DNA encoded library of over 31 billion molecules, opening up this powerful screening technology for academic and non-profit research groups globally. The library includes both commercially available compounds and novel structures synthesized in-house.

Anthropic's library has screened over 100 biological targets from research collaborators worldwide. Hits identified include leads against malaria, tuberculosis and neglected tropical diseases. The shared library model enables researchers to screen billions of molecules for a nominal fee, democratizing access to this advanced drug discovery approach.

Advancing Precision Medicine With DEL

DELs hold great promise for advancing precision medicine and developing therapeutics targeted to specific patient genomes or biomarkers. Researchers can now screen entire genomic or protease mutant libraries against the growing number of known disease-associated protein variants and mutants.

This allows high-resolution mapping of how genomic changes and mutations alter the binding profiles of drug targets - revealing opportunities for precision therapies. Combining DELs screening with multi-omics patient data also enables the discovery of biomarker-targeted drug candidates from day one of development.

Global Regulatory Acceptance And Clinical Validation

As DELs screening has matured,regulatory agencies are increasingly recognizing the approach. In 2020, the FDA approved the first new drug developed using a DNA encoded library by Astex Pharmaceuticals, called gilteritinib, for the treatment of acute myeloid leukemia. 

This landmark approval demonstrated regulatory acceptance of DELs as an established drug discovery technology. It has encouraged further investment and validation efforts by pharmaceutical companies to advance hits from DNA encoded screening into clinical candidates and new medicines.

With the establishment of large shared public libraries like Anthropic’s, DNA encoded screening is becoming a powerful global resource for drug discovery. It will continue to transform both academic and industrial new drug research by massively expanding the chemical space that can be rapidly explored for novel bioactive DELs are set to play a major role in developing the medicines of tomorrow.

In DNA encoded libraries represent a revolutionary new approach to drug discovery that is being rapidly adopted globally. By enabling high-throughput screening of billions of drug-like molecules against disease targets simultaneously, they have far surpassed traditional screening methods in scale and efficiency. 

Through both industrial applications and public library sharing programs, DNA encoded screening allows researchers worldwide to identify novel lead compounds that may ultimately become new medicines. They are also advancing precision medicine through unbiased exploration of genomic and patient biomarker datasets. With regulatory acceptance growing, DNA encoded libraries will continue to transform drug R&D and deliver new treatments to patients.

Get more insights on this topic:   https://www.ukwebwire.com/global-dna-encoded-library-revolutionizing-drug-discovery-through-dna-encoded-chemical-libraries/

 About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[drmatt123]

DNA-encoded Compound Library in New Drugs Research

DNA-encoded chemical library technology is increasingly being used for lead compound screening to accelerate the development of new drugs. It uses DNA fragments as barcodes to record the structural information of compounds. In a compound library containing hundreds of millions of chemical molecules, each molecule is linked to a unique piece of DNA.

[rootsanalysis]

When a big pharma agrees to spend millions in acquiring a drug discovery company, the world is bound to take note. The same happened earlier this year – the acquisition of Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) was a piece of big news in the drug discovery world, validating the potential of DNA encoded libraries in drug discovery.

The acquisition has allowed Amgen to get a team of experts adept at making and screening billions to trillions of compounds to find promising leads. And Amgen is not the only pharma company that has realized the benefits of this technology. As per a recent study by Roots Analysis, close to 100 strategic partnerships related to DNA-encoded libraries have been forged between pharma players and academic institutes and/or technology providers during the period 2010-2019. The rise in partnership activity is a clear indicator of the increasing popularity of this unique technology. Here, we will look at some of the key trends that are shaping up this industry:

-

https://www.rootsanalysis.com/blog/2019/12/27/dna-encoded-libraries-big-pharma/

[pharmaphorumuk]

Almirall signs atopic dermatitis R&D deal with Hitgen

Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for moderate to severe atopic dermatitis – otherwise known as eczema.

The Spanish dermatology specialist is conducting a multi-target research collaboration with companies using a technology involving DNA-encoded libraries, for targets in atopic dermatitis to develop novel oral chemical entities for patients suffering from moderate to severe atopic dermatitis.

DNA-encoded library technology allows for large-scale screening and synthesis of small molecule compounds, with the aim of accelerating the drug discovery process.

Almirall’s move is interesting given that Sanofi has shown that drugs for eczema are highly marketable with its injected drug Dupixent (dupilumab).

But patients may prefer to take oral medicines instead, creating a possible market opportunity for any company able to make a similarly effective oral drug.

Almirall has therefore entered into a collaboration with HitGen, a privately held biotechnology company established since 2012 in Chengdu, China, to establish an advanced lead generation platform based on their DNA-encoded libraries for this specific target.

With a library of nearly 400 billion compounds, Almirall hopes that HitGen will be able to identify compounds that will react with molecular targets linked with eczema.

Under the terms of the agreement, Almirall will provide reagents and material to screen the targets.

HitGen will prosecute screening, hit ID, confirmation and early testing against the selected targets leveraging its proprietary unique DEL Screening platform.

Almirall’s chief scientific officer Bhushan Hardas said: “This agreement keeps us on track to achieve our goal of becoming a leading medical dermatology company. We look forward to collaborate with HitGen in identifying new molecules with the potential of becoming new treatment options for patients with atopic dermatitis”.

Based in Barcelona, Almirall’s total revenues in 2018 were 811 million euros, and had more than 1,800 employees devoted to science.

The post Almirall signs atopic dermatitis R&D deal with Hitgen appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/almirall-signs-atopic-dermatitis-rd-deal-with-hitgen/

[dorcasrempel]

Study finds that aging neurons accumulate DNA damage

MIT neuroscientists have discovered that an enzyme called HDAC1 is critical for repairing age-related DNA damage to genes involved in memory and other cognitive functions. This enzyme is often diminished in both Alzheimer’s patients and normally aging adults.

In a study of mice, the researchers showed that when HDAC1 is lost, a specific type of DNA damage builds up as the mice age. They also showed that they could reverse this damage and improve cognitive function with a drug that activates HDAC1.

The study suggests that restoring HDAC1 could have positive benefits for both Alzheimer’s patients and people who suffer from age-related cognitive decline, the researchers say.

“It seems that HDAC1 is really an anti-aging molecule,” says Li-Huei Tsai, the director of MIT’s Picower Institute for Learning and Memory and the senior author of the study. “I think this is a very broadly applicable basic biology finding, because nearly all of the human neurodegenerative diseases only happen during aging. I would speculate that activating HDAC1 is beneficial in many conditions.”

Picower Institute research scientist Ping-Chieh Pao is the lead author of the study, which appears today in Nature Communications.

DNA repair and aging

There are several members of the HDAC family of enzymes, and their primary function is to modify histones — proteins around which DNA is spooled. These modifications control gene expression by blocking genes in certain stretches of DNA from being copied into RNA.

In 2013, Tsai’s lab published two papers that linked HDAC1 to DNA repair in neurons. In the current paper, the researchers explored what happens when HDAC1-mediated repair fails to occur. To do that, they engineered mice in which they could knock out HDAC1 specifically in neurons and another type of brain cells called astrocytes.

For the first several months of the mice’s lives, there were no discernable differences in their DNA damage levels or behavior, compared to normal mice. However, as the mice aged, differences became more apparent. DNA damage began to accumulate in the HDAC1-deficient mice, and they also lost some of their ability to modulate synaptic plasticity — changes in the strength of the connections between neurons. The older mice lacking HCAC1 also showed impairments in tests of memory and spatial navigation.

The researchers found that HDAC1 loss led to a specific type of DNA damage called 8-oxo-guanine lesions, which are a signature of oxidative DNA damage. Studies of Alzheimer’s patients have also shown high levels of this type of DNA damage, which is often caused by accumulation of harmful metabolic byproducts. The brain’s ability to clear these byproducts often diminishes with age.

An enzyme called OGG1 is responsible for repairing this type of oxidative DNA damage, and the researchers found that HDAC1 is needed to activate OGG1. When HDAC1 is missing, OGG1 fails to turn on and DNA damage goes unrepaired. Many of the genes that the researchers found to be most susceptible to this type of damage encode ion channels, which are critical for the function of synapses.

Targeting neurodegeneration

Several years ago, Tsai and Stephen Haggarty of Harvard Medical School, who is also an author of the new study, screened libraries of small molecules in search of potential drug compounds that activate or inhibit members of the HDAC family. In the new paper, Tsai and Pao used one of these drugs, called exifone, to see if they could reverse the age-related DNA damage they saw in mice lacking HDAC1.

The researchers used exifone to treat two different mouse models of Alzheimer’s, as well as healthy older mice. In all cases, they found that the drug reduced the levels of oxidative DNA damage in the brain and improved the mice’s cognitive functions, including memory.

Exifone was approved in the 1980s in Europe to treat dementia but was later taken off the market because it caused liver damage in some patients. Tsai says she is optimistic that other, safer HDAC1-activating drugs could be worth pursuing as potential treatments for both age-related cognitive decline and Alzheimer’s disease.

“This study really positions HDAC1 as a potential new drug target for age-related phenotypes, as well as neurodegeneration-associated pathology and phenotypes,” she says.

Tsai’s lab is now exploring whether DNA damage and HDAC1 also play a role in the formation of Tau tangles — misfolded proteins in the brain that are a signature of Alzheimer’s and other neurodegenerative diseases.

The research was funded by the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and a Glenn Award for Research in Biological Mechanisms of Aging.

Study finds that aging neurons accumulate DNA damage syndicated from https://osmowaterfilters.blogspot.com/

[kathleenseiber]

Lab-made molecules store image of Picasso drawing

Storing image files in mixtures containing custom-synthesized small molecules is a milestone for molecular data storage, researchers report.

In all, the researchers stored more than 200 kilobytes of data, which they say is the most stored to date using small molecules. That’s not a lot of data compared to traditional means of storage, but it is significant progress in terms of small molecule storage, they say.

“The large numbers of unique small molecules, the amount of data we can store, and the reliability of the data readout shows real promise for scaling this up even further,” says coauthor Jacob Rosenstein, an assistant professor in the School of Engineering at Brown University.

More and more data

As the data universe continues to expand, researchers are working to find new and more compact means of storage. By encoding data in molecules, it may be possible to store the equivalent of terabytes of data in just a few millimeters of space.

Most research on molecular storage has focused on long-chain polymers like DNA, well known carriers of biological data. But there are potential advantages to using small molecules as opposed to long polymers. Small molecules are potentially easier and cheaper to produce than synthetic DNA, and in theory have an even higher storage capacity.

The researchers have been working to find ways of making small-molecule data storage feasible and scalable.

To store data, the team uses small metal plates arrayed with 1,500 tiny spots less than a millimeter in diameter. Each spot contains a mixture of molecules. The presence or absence of different molecules in each mixture indicate the digital data. The number of bits in each mixture can be as large as the library of distinct molecules available for mixing. The data can then be read out using a mass spectrometer, which can identify the molecules present in each well.

In a paper from last year, the team showed that they could store image files in the kilobyte range using some common metabolites, the molecules that organisms use to regulate metabolism.

For this new work, the researchers were able to vastly expand the size of their library—and thereby the sizes of the files they could encode—by synthesizing their own molecules.

Scaling up molecular data storage

The team made their molecules using Ugi reactions—a technique often used in the pharmaceutical industry to quickly produce large numbers of different compounds. Ugi reactions combine four broad classes of reagents (an amine, an aldehyde or a ketone, a carboxylic acid, and an isocyanide) into one new molecule.

By using different reagents from each class, the researchers could quickly produce a wide array of distinct molecules. For this work, the team used five different amines, five aldehydes, 12 carboxylic acids, and five isocyanides in different combinations to create 1,500 distinct compounds.

“The advantage here is the potential scalability of the library,” Rubenstein says. “We use just 27 different components to make a 1,500-molecule library in one day. That means we don’t have to go out and find 1,500 unique molecules.”

From there, the team used sub-libraries of compounds to encode their images. They used a 32-compound library to store a binary image of the Egyptian god Anubis. And they used a 575-compound library to encode a 0.88-megapixel Picasso drawing of a violin.

The large number of molecules available for the chemical libraries also enabled the researchers to explore alternate encoding schemes that made the readout of data more robust. While mass spectrometry is highly precise, it’s not perfect. So as with any system used to store or transmit data, this system will need some form of error correction.

“The way we design the libraries and read out the data includes extra information that lets us correct some errors,” says first author Chris Arcadia, a graduate student. “That helped us streamline the experimental workflow and still get accuracy rates as high as 99%.”

There’s still more work to be done to bring this idea up to a useful scale, the researchers say. But the ability to create large chemical libraries and use them for encoding ever larger files suggests the approach can indeed scale up.

“We’re no longer limited by the size of our chemical library, which is really important,” Rosenstein says. “That’s the biggest step forward here. When we started this project a few years ago, we had some debates about whether something of this scale was even experimentally feasible. So it’s really encouraging that we’ve been able to do this.”

The study appears in Nature Communications. Funding for the work came from DARPA and the National Science Foundation.

Source: Brown University

The post Lab-made molecules store image of Picasso drawing appeared first on Futurity.

Lab-made molecules store image of Picasso drawing published first on https://triviaqaweb.weebly.com/

[yervand63]

Week In Review: 3 China Biopharmas Announce Plans For Shanghai/Hong Kong IPOs

Week In Review: 3 China Biopharmas Announce Plans For Shanghai/Hong Kong IPOs

Deals and Financings

HitGen, a Chengdu small molecule discovery company, has been approved for a $97 million IPO on Shanghai’s new Science and Technology Innovation Board. HitGen has built a DNA-encoded library that contains nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. The company is a partnering wonder, having formed more than 60 drug discovery…

[colinwilson11]

Global DNA Encoded Library Market Will Grow At Highest Pace Owing To Rising Demand For Targeted Drug Discovery

DNA encoded library is an innovative approach that employs DNA sequences to encode large chemical libraries for drug discovery. DNA encoded libraries provide advantages like screening of millions of compounds in parallel and facilitating drug discovery research. The technique involves encoding large collections of small molecules, peptides or oligonucleotides with short DNA tags and then screening them for potential hits. This enables high-throughput screens focusing on specific targets for applications in drug discovery, chemical biology and systematic evolution of ligands by exponential enrichment (SELEX).

The Global DNA Encoded Library Market is estimated to be valued at US$ 0.8 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the Global DNA Encoded Library are BOC Sciences, DyNAbind, Edelris, GenScript, and HitGen. These players are adopting strategies like collaborations, investments in R&D and new product launches to strengthen their market position. The growing demand for effective therapeutics against various diseases is also boosting the demand for DNA encoded library-based drug discovery worldwide. Additionally, technological advancements like next generation sequencing and mass spectrometry is further enhancing the screening capabilities and fueling the growth of this market.

Market Trends

Some of the key trends driving the growth of the Global DNA Encoded Library market include rising adoption of DNA-encoded library techniques by pharmaceutical companies and growth of clinical trials. The traditional drug discovery methods are being replaced with DNA-encoded techniques owing to their advantages. They enable screening libraries of billions of compounds efficiently in a high-throughput manner. Another trend is the increasing partnerships between technology providers and end-users to accelerate the drug discovery process using DNA-encoded library platforms.

Market Opportunities

The untapped potential of emerging economies and growing research in genomic applications presents huge opportunities for players in this market. Rapid advances in DNA synthesis and sequencing technologies are further expanding the applications of DNA-encoded libraries. Adoption of artificial intelligence and machine learning can also enhance the screening and data analysis capabilities. Development of customized DNA-encoded libraries focused on specific disease pathways will witness high demand in coming years.

Impact Of Covid-19 On Global DNA Encoded Library Market Growth:

The outbreak of Covid-19 pandemic severely impacted the growth of global DNA encoded library market in the initial months of 2020. Various social restrictions imposed by governments like lockdowns and social distancing norms disrupted the supply chain and halted research activities at labs and research institutions globally. This led to delays in drug discovery programs utilizing DNA encoded libraries. Many biopharma companies also shifted resources to focus on Covid-19 vaccine and treatment research in the short term.

However, as research communities and industries adapted to the new normal, activity levels recovered gradually in 2021. The pandemic also highlighted the importance of therapeutics for infectious diseases, boosting investment in areas like antibiotic discovery utilizing DNA encoded libraries. Many players in the market also expedited development of Covid-19 antiviral and treatment libraries. Going forward, market players are focusing on digitalization of operations and remote collaborations to make discovery processes more resilient to future disruptions. Governments are also providing increased funding for genomics and biotech to accelerate development of new drugs.

Concentration Of Global DNA Encoded Library Market In Terms Of Value:

North America region currently accounts for the largest share of global DNA encoded library market in terms of value, estimated at over 40% in 2024. This is due to presence of major pharmaceutical players and contract research organizations (CROs) actively utilizing these libraries for drug discovery programs in the US and Canada. Countries like the US also provide favorable funding environment for genomic and biotech research. Europe is the second largest regional market led by presence of large pharma companies and academic research institutes in countries like UK, Germany and France. The market is also witnessing fastest growth in Asia Pacific region led by China and India. This is attributed to increasing government investments in healthcare sector, emerging biotech industry and growing expertise in DNA sequencing and library construction technologies.

Fastest Growing Region In The Global DNA Encoded Library Market:

Asia Pacific region is poised to emerge as the fastest growing regional market for DNA encoded libraries during the forecast period from 2024 to 2031. This growth can be attributed to increasing government emphasis and funding for research in genomics, biotech and synthetic biology in emerging economies like China and India. Favorable business environment and presence of skilled labor are also attracting many global library developers and pharmaceutical companies to set up research and manufacturing facilities in the region. In addition, the region provides significant cost advantages compared to developed markets for drug discovery processes. With improving standards and widespread adoption of DNA encoded library technologies, Asia Pacific will continue dominating the growth of worldwide market in the coming years.

Get more insights on this topic:   https://www.pressreleasebulletin.com/global-dna-encoded-library-market-set-for-high-growth-due-to-advancements-in-dna-screening-technologies/

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Global DNA Encoded Library Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global DNA Encoded Library Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Global DNA Encoded Library Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Global DNA Encoded Library Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global DNA Encoded Library Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global DNA Encoded Library Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Global DNA Encoded Library Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Global DNA Encoded Library Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[drmatt123]

DNA-based Therapy

DNA-based drug development and production are playing an increasingly important role in modern medicine. The application of DNA-based therapy mainly includes a DNA-encoded compound library for new drugs research, genetically engineered bacterias drugs, nuelic acid vaccines, recombinant antibodies, small nucleic acid drugs, and gene editing.

[medicaldevicesblog-blog]

Genetic Screening for Embryo Selection does not interfere with Live Birth Rates

HitGen and Merck Collaborates For DNA Library ScreeningHitGen and Merck have updated their licensing agreement to a full-fledged drug discovery collaboration in order to screen DNA-encoded libraries for new small-molecule assets. HitGen will be providing its technology platform to design and build multiple libraries for Merck’s international efforts under Merck Sharp & Dohme, or MSD.HitGen will be screening its libraries of more than 200 billion compounds against MSD’s selected therapeutic targets. The newly discovered compounds will be licensed to MSD for research work and MSD will be supporting Hitchen's research.Emma Parmee, the VP of MSD’s global discovery chemistry said, “This expanded collaboration builds upon the strong relationship we have developed with researchers at HitGen as we apply the DEL technology across our portfolio.”The company has also signed a multitarget discovery collaboration with various other pharma companies, such as Pfizer, Sanofi, Johnson & Johnson, Boehringer Ingelheim, Aduro Biotech and research institutes like Cancer Research U.K., the Scripps Research Institute and the California Institute for Biomedical Research.HitGen also received a three-year grant from the Bill & Melinda Gates Foundation for therapeutic discovery against malaria and tuberculosis.Jin Li, the CEO, Founder and Chairman of HitGen said, “HitGen continues to grow as a world-class drug discovery organization; In addition to our collaborations with industry partners, we are keenly focused on engaging with world-leading philanthropic and academic institutions to provide new solutions for patients with unmet medical needs.”The post HitGen and Merck Collaborates For DNA Library Screening appeared first on Drugdu.com

[sandlerresearch]

HitGen LTD - Pharmaceuticals & Healthcare - Deals and Alliances Profile published on

http://www.sandlerresearch.org/hitgen-ltd-pharmaceuticals-healthcare-deals-and-alliances-profile.html

HitGen LTD - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

HitGen LTD (HitGen) is a drug company that concentrates on hit identification and lead generation in the early phases of drug discoveries and development. The company offers OpenDEL, a collection of DNA encoded library compounds based on distinct, diverse and drug structures. It provides biological reagents, edge technology and services for progression of projects and services. HitGen’s services include lead generation by DNA encoded chemical libraries; hit to lead expansion and lead optimization; custom compound and compound library synthesis and others. The company’s research support capabilities comprise protein expression and purification, chemical library design and synthesis, in-vitro screening and affinity selection, and others. It serves contract research organizations and pharmaceutical industries. HitGen is headquartered in Chengdu, China.

HitGen LTD – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. – Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. – Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. – Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. – Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector. – Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. – Business Description – A brief description of the company’s operations. – Key Employees – A list of the key executives of the company. – Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company. – Key Competitors – A list of the key competitors of the company. – Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements – The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy – The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company – Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. – The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company – Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research – Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

[houstonlibrarian]

New Post has been published on Librarian Chat

New Post has been published on http://www.librarianchat.com/?p=352057

How DNA-encoded libraries are revolutionizing drug discovery - The Biological SCENE

The Biological SCENEHow DNA-encoded libraries are revolutionizing drug discoveryThe Biological SCENEDNA-encoded libraries let researchers screen millions, billions, and even trillions of chemical compounds in a single, simple experiment, thanks to a DNA tag that encodes how each component in the library was made. Although the technology was invented …und weitere …read more

Read more here:: http://news.google.com/news/url?sa=t&fd=R&ct2=de&usg=AFQjCNGrwHG2tf27ILe9noOE-m9nz9Ix6Q&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779535203045&ei=tKtHWYD_KdDGzAKIppHwCw&url=http://cen.acs.org/articles/95/i25/DNA-encoded-libraries-revolutionizing-drug.html

[pruzzels]

“You ask, Aristippus, and I tell you / it’s in the waiting; that the moment, like a stag / may arrive at your doorstep as if from a cloud / and disappear before you know it, / not even the after-trace of a phantasm; / and you will have missed it for all your scheming, / your daydreaming about lofty verses and fame, / your lunging and casting about like a spaniel / barking his way into the middle of a slough, / then unable to get out.” Kleinzahler, from “Epistle XIV”, 2003

  A couple of days worth of scribbles from one Google Doc. Much recent work is for publication elsewhere. The blog may be relatively quiet. Apologies. Enjoy my head turned inside out and gently browned.

03192017

In astronomy, the Pleiades, or Seven Sisters (Messier 45 or M45), is an open star cluster containing middle-aged, hot B-type stars located in the constellation of Taurus.

moving-words in sappho:

watched, go down, …

In linguistics, a compound verb or complex predicate is a multi-word compound that functions as a single verb. One component of the compound is a light verb or vector, which carries any inflections, indicating tense, mood, or aspect, but provides only fine shades of meaning. The other, “primary”, component is a verb or noun which carries most of the semantics of the compound, and determines its arguments. It is usually in either base or [in Verb + Verb compounds] conjunctive participial form.

In modern grammar, a particle is a function word that must be associated with another word or phrase to impart meaning, i.e., does not have its own lexical definition. On this definition, particles are a separate part of speech and are distinct from other classes of function words, such as articles, prepositions, conjunctions and adverbs. Languages vary widely in how much they use particles, some using them extensively and others more commonly using alternative devices such as prefixes/suffixes, inflection, auxiliary verbs and word order. Particles are typically words that encode grammatical categories (such as negation, mood, tense, or case), clitics, or fillers or (oral) discourse markers such as well, um, etc. Particles are never inflected.

there are about 200 irregular verbs;

The copula verb be has a larger number of different inflected forms, and is highly irregular.

[Pleiades] was later mythologised as the name of seven divine sisters, whose name was imagined to derive from that of their mother Pleione, effectively meaning “daughters of Pleione”. In reality, the name of the star cluster almost certainly came first, and Pleione was invented to explain it.

… goes, am

In about 300 BC, a doctor was summoned to diagnose the illness afflicting Antiochus, crown prince of the Seleucid empire in Syria. The young man’s symptoms included a faltering voice, burning sensations, a racing pulse, fainting, and pallor. In his biography of Antiochus’ father, Seleucus I, Plutarch reports that the symptoms manifested themselves only when Antiochus’ young stepmother Stratonice was in the room. The doctor was therefore able to diagnose the youth’s malady as an infatuation with her. The cause of the illness was clearly erotic, because the symptoms were “as described by Sappho.” The solution was simple: Antiochus’ father divorced Stratonice and let his son marry her instead. … Sappho has probably had more words written about her in proportion to her own surviving output than any other writer.

03202017

“If the repression is not completely effective, then a state of anxiety can be stimulated by the unconscious mind producing threatening feelings without the patient being aware of the reason for the anxiety. This is where the descriptions of the demons may help the incantation treat the sufferer. The process of denial can be influenced by focusing on the demons as the cause of the anxiety, particularly if it remind the patient of those intimate feelings which were originally repressed. Repression, as explained by Freud, takes many forms, some of which can clearly be detected in Mesopotamian incantations.” Freud, Magic and Mesopotamia: How the Magic Works

03212017

jacobus: “Just as literal or symbolic acts of erasure challenge the authority of iconic images, Dadaist techniques of collage overturn received narratives and subvert aesthetic hierarchies.” 19

03222017

“more equal” montfort 85

03232017

“I maintain my Twitter and Facebook for professional purposes.” “I’m not allergic to mold.”

03252017

Rukeyser: When I wrote of the women in their dances and wildness, it was a mask, on their mountain, gold-hunting, singing, in orgy, it was a mask; when I wrote of the god, fragmented, exiled from himself, his life, the love gone down with song, it was myself, split open, unable to speak, in exile from myself.

There is no mountain, there is no god, there is memory of my torn life, myself split open in sleep, the rescued child beside me among the doctors, and a word of rescue from the great eyes.

No more masks! No more mythologies!

Now, for the first time, the god lifts his hand, the fragments join in me with their own music.

”Emily Dickinson’s strictness, sometimes almost a slang of strictness, speaks with an intellectually active, stimulated quick music.” Rukeyser

“leveling of man” masons, heard in doc on burns

My favorite Queen song is, BY FAR, Princes of the Universe. What does that say about me?

03282017

Salcedo examines world violence and talks about the experiences of the victims. Refuses to let them be forgotten. Elevates them. The goal here is what? … So that we don’t forget? So that we can empathize… and change? So that in the split second before the sword meets flesh the executioner can pull up, pull out, disengage?

03292017

Reading Ruefle’s On Sentimentality: The internet as “Great Puddle of Sentimentality”. No time to expand on that right now, but good idea for an essay. Use her bibliography as a starting point. (John Gardner: “causeless emotion.”)

Bestowing upon one the permission to “see better”/”perceive better”/”sense better”/feel better” is the greatest gift a poet can convey. This is said in some form by Mary Ruefle in several sources. (Muck, a YouTube video from the Library of Congress where she speaks with Ron Charles, probably elsewhere…)

040220171022

“singing of black despair is some consolation for having to endure it.” Badiou, Black, 5

040520172010

I have a weird relationship with brilliant and eccentric people. I think a lot about how brilliance and that powerful cult-of-personality persona exhibited by a lot of religious/cult leaders a/o self-help gurus, celebrities, political figures, etc etc, are connected. I’ve been close to a few really brilliant people who can’t get along with others. is it a choice? a gift? a curse?

041020170713

“Poetry is never encoded–it is never a convert operation whose information is ciphered and must be deciphered–and yet it does incline toward self-concealment, insofar as it concentrates intently on what words conceal, or, to put it another way, on what language seeks to reveal. // It concentrates on the inside in an attempt to reverse the situation; to turn it inside out. // Every word carries a secret inside itself; it’s called etymology. // It is the DNA of a word.” Mary Ruefle, p91

Recent Notes A couple of days worth of scribbles from one Google Doc. Much recent work is for publication elsewhere.